K2 Principal Fund’s PharmaCyte Biotech PMCB Stock Holding History

K2 Principal Fund’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-209,266	Closed	-$400K	–	345
2024 Q3	$400K	Sell	209,266 -118,237	-36%	-$220K	0.06%	172
2024 Q2	$642K	Hold	327,503	–	–	0.12%	130
2024 Q1	$776K	Buy	327,503 +22,890	+8%	+$49.5K	0.13%	132
2023 Q4	$655K	Buy	304,613 +46,132	+18%	+$100K	0.08%	133
2023 Q3	$543K	Buy	258,481 +104,249	+68%	+$266K	0.11%	110
2023 Q2	$441K	Sell	154,232 -569,039	-79%	-$1.71M	0.1%	125
2023 Q1	$2.06M	Sell	723,271 -8,834	-1%	-$26K	0.28%	86
2022 Q4	$2.15M	Buy	732,105 +120,942	+20%	+$346K	0.33%	64
2022 Q3	$1.47M	Buy	611,163 +520,068	+571%	+$1.32M	0.17%	111
2022 Q2	$204K	Buy	+91,095	New	+$199K	0.02%	224

Other funds holding PMCB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $187M AUM 179.87% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

K2 Principal Fund's PMCB Position: Q4 2024 in Review

K2 Principal Fund sold out of PharmaCyte Biotech (PMCB) in Q4 2024, closing a stake of 209,266 shares — an estimated $400K sold.

K2 Principal Fund first reported a position in PMCB in Q2 2022 and held it in 10 quarters. The position peaked at $2.15M in Q4 2022. 21 funds tracked by Wall St. Rank hold PMCB as of Q4 2024.

K2 Principal Fund reported no remaining PharmaCyte Biotech position as of Q4 2024 after selling out during the quarter.
K2 Principal Fund sold 209,266 PharmaCyte Biotech shares in Q4 2024, an estimated $400K.
K2 Principal Fund first reported a position in PharmaCyte Biotech in Q2 2022 and held it in 10 quarters.
K2 Principal Fund's PharmaCyte Biotech position peaked at $2.15M in Q4 2022.
21 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q4 2024.

Based on K2 Principal Fund's 13F filing for Q4 2024, filed 14 Feb 2025.